Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Cash & Equivalents for 10 consecutive years, with $58.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 69.45% to $58.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.1 million through Dec 2025, down 69.45% year-over-year, with the annual reading at $58.1 million for FY2025, 69.45% down from the prior year.
  • Cash & Equivalents hit $58.1 million in Q4 2025 for Sutro Biopharma, down from $65.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $235.1 million in Q2 2023 to a low of $28.9 million in Q1 2022.
  • Historically, Cash & Equivalents has averaged $84.5 million across 5 years, with a median of $65.6 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: tumbled 85.25% in 2021 and later soared 215.17% in 2022.
  • Year by year, Cash & Equivalents stood at $30.4 million in 2021, then soared by 55.37% to $47.3 million in 2022, then soared by 46.59% to $69.3 million in 2023, then skyrocketed by 174.74% to $190.3 million in 2024, then tumbled by 69.45% to $58.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for STRO at $58.1 million in Q4 2025, $65.9 million in Q3 2025, and $64.0 million in Q2 2025.